For more information, please visit www.DecoyTx.com. About Salarius Pharmaceuticals, Inc. Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company with two drug candidates for ...

Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX). As announced on January 13, ...

Salarius Pharmaceuticals, Inc. has reported progress in its planned merger with Decoy Therapeutics, which is expected to enhance the development of novel peptide conjugate therapeutics aimed at ...

CEO and Director of Salarius Pharmaceuticals (SLRX). “As previously announced, the MDACC investigator-initiated hematologic cancer trial is active and enrolling patients, and we look forward to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Langer, ScD will join the company’s Scientific Advisory Board (SAB) upon the successful completion of Decoy’s merger with Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX). As announced on January ...